Connect with us

Published

on

KFF Health News Dec 17 2024

Many of President-elect Donald Trump's candidates for federal health agencies have promoted policies and goals that put them at odds with one another or with Trump's choice to run the Department of Health and Human Services, Robert F. Kennedy Jr., setting the stage for internal friction over public health initiatives.

The picks hold different views on matters such as limits on abortion, the safety of childhood vaccines, the covid-19 response, and the use of weight-loss medications. The divide pits Trump picks who adhere to more traditional and orthodox science, such as the long-held, scientifically supported findings that vaccines are safe, against often unsubstantiated views advanced by Kennedy and other selections who have claimed vaccines are linked with autism.

The Trump transition team and the designated nominees mentioned in this article did not respond to requests for comment.

It's a potential "team of opponents" at the government's health agencies, said Michael Cannon, director of health policy studies at the Cato Institute, a libertarian policy organization.

Kennedy, he said, is known for rejecting opposing views when confronted with science.

"The heads of the FDA and NIH will be spending all their time explaining to their boss what a confidence interval is," Cannon said, referring to a statistical term used in medical studies.

Those whose views prevail will have significant power in shaping policy, from who is appointed to sit on federal vaccine advisory committees to federal authorization for covid vaccines to restrictions on abortion medications. If confirmed as HHS secretary, Kennedy is expected to set much of the agenda.

"If President Trump's nomination of RFK Jr. to be secretary is confirmed, if you don't subscribe to his views, it will be very hard to rise in that department," said Amesh Adalja, an infectious disease specialist and senior scholar at the Johns Hopkins Center for Health Security. "They will need to suppress their views to fit with RFK Jr's. In this administration, and any administration, independent public disagreement isn't welcome."

Kennedy is chair of Children's Health Defense, an anti-vaccine nonprofit. He has vowed to curb the country's appetite for ultra-processed food and its incidence of chronic disease. He helped select Trump's choices to lead the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. If confirmed, he would lead them from the helm of HHS, with its more than $1.7 trillion budget.

Clashes are likely. Kennedy has supported access to abortion until a fetus is viable. That puts him at odds with Dave Weldon, the former Florida congressman whom Trump has chosen to run the CDC. Weldon, a physician, is an abortion opponent who wrote one of the major laws allowing health professionals to opt out of participating in the procedure.

Weldon would head an agency that's been in the crosshairs of conservatives since the covid pandemic began. He has touted his "100% pro-life voting record" on his campaign website. (He unsuccessfully ran earlier this year for a seat in Florida's House of Representatives.)

Trump has said he would leave decisions about abortion to the states, but the CDC under Weldon could, for example, fund studies on abortion risks. The agency could require states to provide information about abortions performed within their borders to the federal government or risk the loss of federal funds.

Weldon, like Kennedy, has questioned the safety of vaccines and has said he believes they can cause autism. That's at odds with the views of Marty Makary, a Johns Hopkins surgeon whom Trump plans to nominate for FDA commissioner. The British American said on the "Brian Kilmeade Show" on Fox News Radio that vaccines "save lives," although he added that it's good to question the U.S. vaccine schedule for children.

The American Academy of Pediatricians encourages parents and their children's doctors to stick to the recommended schedule of childhood vaccines. "Nonstandard schedules that spread out vaccines or start when a child is older put entire communities at risk of serious illnesses, including infants and young children," the group says in guidance for its members.

Jay Bhattacharya, a doctor and economist who is Trump's selection to lead NIH, has also supported vaccines.

Kennedy has said on NPR that federal authorities under his leadership wouldn't "take vaccines away from anybody." But the FDA oversees approval of vaccines, and, under his leadership, the agency could put vaccine skeptics on advisory panels or could make changes to a program that largely protects vaccine makers from consumer injury lawsuits.

"I do believe that autism does come from vaccines," Kennedy said in 2023 on Fox News. Many scientific studies have discredited the claim that vaccines cause autism. Related StoriesAI-generated handoff notes: Study assesses safety and accuracy in emergency medicineStudy: Brain volume changes correlate with social behavior differences in psychiatric conditionsResearch uncovers dietary patterns influencing Mediterranean Diet adherence

Ashish Jha, a doctor who served as the White House covid response coordinator from 2022 to 2023, noted that Bhattacharya and Makary have had long and distinguished careers in medicine and research and would bring decades of experience to these top jobs. But, he said, it "is going to be a lot more difficult than they think" to stand up for their views in the new administration.

It's hard "to do things that displease your boss, and if [Kennedy] gets confirmed, he will be their boss," Jha said. "They have their work cut out for them if they're going to stand up for their opinions on science. If they don't, it will just demoralize the staff."

Most of Trump's picks share the view that federal health agencies bungled the pandemic response, a stance that resonated with many of the president-elect's voters and supporters — even though Trump led that response until Joe Biden took office in 2021.

Kennedy said in a 2021 Louisiana House oversight meeting that the covid vaccine was the "deadliest" ever made. He has cited no evidence to back the claim.

Federal health officials say the vaccines have saved millions of lives around the globe and offer important protection against covid. Protection lasts even though their effectiveness wanes over time.

The vaccines' effectiveness against infection stood at 52% after four weeks, according to a May study in The New England Journal of Medicine, and their effectiveness against hospitalization was about 67% after four weeks. The vaccines were produced through Operation Warp Speed, a public-private partnership Trump launched in his first term to fast-track the shots as well as other treatments.

Makary criticized covid vaccine guidance that called for giving young children the shots. He argued that, for many people, natural immunity from infections could substitute for the vaccine. Bhattacharya opposed measures used to curb the spread of covid in 2020 and advised that everyone except the most vulnerable go about their lives as usual. The World Health Organization warned that such an approach would overwhelm hospitals.

Mehmet Oz, Trump's choice to head the Centers for Medicare & Medicaid Services, an agency within HHS, has said the vaccines were oversold. He promoted the use of the anti-malaria drug hydroxychloroquine as a treatment. The FDA in 2020 revoked emergency authorization of hydroxychloroquine for covid, saying that it was unlikely to be effective against the virus and that the risk of dangerous side effects was too high.

Janette Nesheiwat, meanwhile, a former Fox News contributor and Trump's pick for surgeon general, has taken a different stance. The doctor described covid vaccines as a gift from God in a Fox News opinion piece.

Kennedy's qualms about vaccines are likely to be a central issue early in the administration. He has said he wants federal health agencies to shift their focus from preparing for and combating infectious disease to addressing chronic disease.

The shifting focus and questioning of vaccines concern some public health leaders amid the spread of the H5N1 bird flu virus among dairy cattle. There have been 60 human infections reported in the U.S. this year, all but two of them linked to exposure to cattle or poultry.

"Early on, they're going to have to have a discussion about vaccinating people and animals" against bird flu, said Georges C. Benjamin, executive director of the American Public Health Association. "We all bring opinions to the table. A department's cohesive policy is driven by the secretary."

This article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism. Source:

KFF Health News

Continue Reading

Business

Monzo lines up bankers to spearhead blockbuster £6bn float

Published

on

By

Monzo lines up bankers to spearhead blockbuster £6bn float

Monzo, the digital bank which counts one in five British adults among its customers, is closing in on the appointment of investment bankers to spearhead a stock market listing valuing it at more than £6bn.

Sky News has learnt that Monzo is working with Morgan Stanley, the Wall Street giant, on a series of meetings with potential investors ahead of an initial public offering which could take place as early as the first half next year.

People close to the company said this weekend that bankers would be formally hired to work on the listing within months, with Morgan Stanley now expected to be handed a key role on the deal.

The timing, size and location of an IPO are still to be determined and will depend on market conditions in London and New York, both of which have been buffeted by Donald Trump’s introduction of swingeing trade tariffs.

However, London is currently seen as the most likely listing venue for Monzo by board members and investors, according to people close to the situation.

The company, which saw its valuation soar to £4.5bn last year after primary and secondary share sales, is considering a further sale of existing shares to allow early investors and employees to cash in, although a decision to proceed has not yet been taken.

Monzo has more than 11m UK retail customers, making it the seventh-largest British bank by customer numbers, and 600,000 business customers.

More from Money

Founded a decade ago, it has become one of Britain’s most successful, and valuable, fintech companies.

It employs close to 4,000 people.

Last year, it raised more than £500m by selling newly issued shares to a group of investors led by Capital G, a division of Alphabet-owned Google.

That primary share sale valued the business at £4.1bn.

An IPO, including any new capital raised, would be likely to value Monzo at more than £6bn, and potentially in the region of £7bn, according to banking sources.

Last year’s secondary share sale saw existing Monzo investors StepStone Group and GIC, the Singaporean sovereign wealth fund, buying stock from employees.

The company is now profitable and has diversified into investments and instant access savings accounts.

It has also launched pensions products and accounts aimed at under-16s.

Read more from Sky News:
Trump floats China tariff cut
Money blog: TV chef on ‘ridiculously good’ supermarket dessert

Monzo is among a new generation of banks which have emerged since the last financial crisis and begun to accumulate a significant share of the UK retail banking market.

Rivals include Starling Bank and Revolut, which was valued at $45bn in its last fundraising and was awarded a banking licence by British regulators last year after a protracted process.

Monzo has recovered spectacularly from a difficult period in 2020 when it emerged that the City watchdog was investigating it for potential breaches of anti-money laundering and financial crime rules.

It has revamped its corporate structure as it pursues an international expansion aimed at enticing new investors to its strategy for long-term growth.

The company has been exploring acquisition opportunities in the US and Europe, although a major deal is not thought to be imminent.

Monzo Bank Holding Group was established to avoid the company facing punitive capital treatment by British regulators as it launches in new overseas markets.

Other Monzo investors include the Chinese group Tencent, Passion Capital, Accel, General Catalyst and Hedosophia.

Monzo is run by TS Anil, its chief executive, and chaired by Gary Hoffman, the banker who salvaged Northern Rock after its nationalisation in 2008.

This weekend, a Monzo spokesperson declined to comment.

Continue Reading

Sports

Jets’ Hellebuyck posts 1st playoff shutout since ’21

Published

on

By

Jets' Hellebuyck posts 1st playoff shutout since '21

The sea of white in Winnipeg chanted “M-V-P!” in unison during the Jets‘ Game 2 win over the Dallas Stars on Friday night. Goalie Connor Hellebuyck heard and appreciated those chants.

“It means a whole lot. I love this crowd. I love this city,” said Hellebuyck, who stopped 21 shots in Winnipeg’s 4-0 victory that evened their Western Conference semifinal series at 1-1.

It was Hellebuyck’s first playoff shutout since a 1-0 blanking of the Edmonton Oilers in the first round in 2021, and the fourth postseason shutout of his career. Hellebuyck led the NHL with eight shutouts in the regular season, which helped him become a finalist for the Hart Trophy as league MVP and for the Vezina Trophy as the NHL’s top goaltender, an award he won last season and in 2020.

Prior to Friday night, he had not been that same goaltender in the postseason.

Considered by many the best netminder in the world, Hellebuyck was the worst goalie statistically in the 2025 Stanley Cup playoffs entering Game 2. He was 4-4 with an .836 save percentage, the lowest for any goalie with at least three postseason games played. He was last in the playoffs through eight games with a minus-9.68 goals saved above expected. He had a 3.75 goals-against average as well, after sporting a GAA of 2.00 and a .925 save percentage in the regular season.

Yet the Jets’ faith in their goaltender never wavered.

“We rely on him. Sometimes too much. But he was incredible tonight,” said defenseman Josh Morrissey, who missed Game 1 against Dallas and most of Game 7 against St. Louis with an injury. “That’s what he does every night for us. He’s an incredible goaltender. He makes very difficult saves look very easy, routinely and often. You could tell he was feeling it tonight. When he’s feeling it like that, it gives the players in front of him a lot of confidence.”

Jets coach Scott Arniel said his goalie was “fantastic” in Game 2.

“Sometimes we take him for granted because he makes the hard look easy, but he had some acrobatic ones tonight,” Arniel said.

That was especially true in the second period. The Jets built a 2-0 lead in the first period on goals by Gabriel Vilardi and Nik Ehlers, whose shot deflected off the skate of Dallas defenseman Esa Lindell. Hellebuyck made nine saves in that opening frame.

“We pushed hard in the second to try and climb back in the game,” said Dallas coach Peter DeBoer. “Hellebuyck made some saves. We get one there, maybe the momentum shifts. But that was the game. He was a good. He was really good. We can always make it more difficult on him, but he was really good.”

After the game, Hellebuyck told Sportsnet that he believed he was back on his game after the shutout win.

“Now it’s locked in. We broke it down to build it back together,” he said. “I like where it’s at. I like where the team’s playing. I’m really excited for the series. It’s been fun.”

Whether the fun continues on the road for Sunday’s Game 3 is anyone’s guess.

Hellebuyck was a disaster in the Jets’ three games in St. Louis, giving up 16 goals on 66 shots (.758 save percentage) and getting pulled in each loss. In his past eight postseason road games, Hellebuyck is 1-7 with a .838 save percentage and a 5.19 goals-against average.

“We’re still playing hockey, and it’s May. That’s fun. It’s the best time of year, because you’ve dialed your game in all year long,” Hellebuyck said.

The Jets said they need to be better in front of their goalie on the road.

“It’s going to be a tough building. They grabbed home ice from us by winning Game 1,” Arniel said. “It’s [about] lessons learned. Take some of the things from that series. We know we have to do a lot of what we did tonight.”

Continue Reading

Sports

Ohtani’s blast caps 6-run 9th in wild Dodgers rally

Published

on

By

Ohtani's blast caps 6-run 9th in wild Dodgers rally

PHOENIX — Shohei Ohtani hit a three-run homer to cap a six-run ninth inning and the Los Angeles Dodgers rallied for a wild 14-11 victory over the Arizona Diamondbacks on Friday night.

The Dodgers trailed 11-8 entering the ninth inning after blowing an early five-run lead.

Andy Pages and Enrique Hernandez hit consecutive run-scoring doubles to open the ninth inning against Kevin Ginkel (0-1). Max Muncy tied it at 11-11 with a run-scoring single and Ryan Thompson replaced Ginkel to face Ohtani.

It didn’t go well for Arizona.

Ohtani, who doubled twice, fell into a 1-2 hole before launching his 12th homer near the pool deck in right to put the Dodgers up 14-11. He finished with four RBIs.

Tanner Scott worked a perfect ninth save in 11 chances.

The Dodgers roughed up Eduardo Rodriguez to take an 8-3 lead through three innings, but couldn’t hold it.

Lourdes Gurriel Jr. hit a tying grand slam in the fifth inning, then Ketel Marte and Randal Grichuk hit solo shots off Alex Vesia (1-0) in the eighth to put Arizona up 11-8.

Pages finished with three RBIs and Hernández extended the Dodgers’ homer streak to 13 straight games with a solo shot in the second inning.

Marte homered twice for the Diamondbacks. Rodriguez allowed eight runs on nine hits in 2⅔ innings.

Continue Reading

Trending